HIV-1 Tat inhibits neprilysin and elevates amyloid β

AIDS

Volumn 19, Issue 2, 2005, Pages 127-135

  Rempel, Hans C ^a   Pulliam, Lynn ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

A degradation; A plaque and HIV dementia; Human brain; Neuron

Indexed keywords

AMYLOID BETA PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; PROTEINASE; TRANSACTIVATOR PROTEIN;

AGING; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; RISK FACTOR;

EID: 15744363144     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200501280-00004     Document Type: Article

References (33)

1. Epstein LG, Gendelman HE. Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms [see comments]. Ann Neurol 1993; 33:429-436.
2. Pulliam L, Herndier BG, Tang NM, McGrath MS. Human immunodeficiency virus-infected macrophages produce soluble factors that cause histological and neurochemical alterations in cultured human brains. J Clin Invest 1991; 87:503-512.
3. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997; 11:1731-1738.
4. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002; 8:136-142.
5. Masliah E, DeTeresa RM, Mallory ME, Hansen LA. Changes in pathological findings at autopsy in AIDS cases for the last 15 years [In Process Citation]. AIDS 2000; 14:69-74.
6. Kusdra L, Mcguire D, Pulliam L. Changes in monocyte/macrophage neurotoxicity in the era of HAART: implications for HIV-associated dementia. AIDS 2002; 16:31-38.
7. Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 1997; 11:1421-1431.
8. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993; 67:277-287.
9. Hudson L, Liu J, Nath A, Jones M, Raghavan R, Narayan O, et al. Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues. J Neurovirol 2000; 6:145-155.
10. Albini A, Ferrini S, Benelli R, Sforzini S, Giunciuglio D, Aluigi MG, et al. HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci USA 1998; 95:13153-13158.
11. Liu Y, Jones M, Hingtgen CM, Bu G, Laribee N, Tanzi RE, et al. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat Med 2000; 6:1380-1387.
12. Cohen AJ, Miller YE. Neuroendocrine differentiation, neuropeptides, and neprilysin. Am J Respir Cell Mol Biol 1999; 21:1-3.
13. Turner AJ, Isaac RE, Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 2001; 23:261-269.
14. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 2000; 6:143-150.
15. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, et al. Metabolic regulation of brain Abeta by neprilysin. Science 2001; 292:1550-1552.
16. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297:353-356.
17. Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 1998; 8:447-453.
18. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416:535-539.
19. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. Jama 2000; 283:1571-1577.
20. Hamazaki H. Cathepsin D is involved in the clearance of Alzheimer's beta-amyloid protein. FEBS Lett 1996; 396:139-142.
21. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta- protein by degradation. J Biol Chem 1998; 273:32730-32738.
22. Fulcher IS, Matsas R, Turner AJ, Kenny AJ. Kidney neutral endopeptidase and the hydrolysis of enkephalin by synaptic membranes show similar sensitivity to inhibitors. Biochem J 1982; 203:519-522.
23. Jellinger KA, Setinek U, Drlicek M, Bohm G, Steurer A, Lintner F. Neuropathology and general autopsy findings in AIDS during the last 15 years. Acta Neuropathol (Berl) 2000; 100:213-220.
24. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95:6448-6453.
25. Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002; 277:32046-32053.
26. Meyer-Luehmann M, Stalder M, Herzig MC, Kaeser SA, Kohler E, Pfeifer M, et al. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci 2003; 6:370-377.
27. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 2003; 100:10417-10422.
28. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, et al. BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer's Disease. Neuron 2004; 41:27-33.
29. Frankel AD, Bredt DS, Pabo CO. Tat protein from human immunodeficiency virus forms a metal-linked dimer. Science 1988; 240:70-73.
30. Rice AP, Chan F. Tat protein of human immunodeficiency virus type 1 is a monomer when expressed in mammalian cells. Virology 1991; 185:451-454.
31. Koken SE, Greijer AE, Verhoef K, van Wamel J, Bukrinskaya AG, Berkhout B. Intracellular analysis of in vitro modified HIV Tat protein. J Biol Chem 1994; 269:8366-8375.
32. Esiri MM, Biddolph SC, Morris CS. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry 1998; 65:29-33.
33. Corder EH, Robertson K, Lannfelt L, Bogdanovic N, Eggertsen G, Wilkins J, et al. HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy [see comments]. Nat Med 1998; 4:1182-1184.